Latest news, Events and Press Releases

Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.

Please direct any media inquiries to communications@curiumpharma.com

News Press releases Events Publications

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

7th January 2026

Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland

23rd December 2025

Curium Further Expands European Availability of Pylclari® – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients With Prostate Cancer

28th January 2025

Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain

10th September 2024

Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer

17th June 2024

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

30th May 2024

Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

6th May 2024

Curium announces first commercial doses in the Netherlands of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

19th March 2024

Curium announces first commercial doses in Italy of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

7th March 2024

Curium announces submission of the marketing authorization application for PYLCLARI®, an innovative (18F)-PSMA PET tracer indicated in adults with prostate cancer to Swissmedic

21st February 2024